IP Verse

Methods For Modulating C9Orf72 Expression - EP2906696

The patent EP2906696 was granted to Ionis Pharmaceuticals on Dec 14, 2022. The application was originally filed on Oct 15, 2013 under application number EP13846313A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2906696

IONIS PHARMACEUTICALS
Application Number
EP13846313A
Filing Date
Oct 15, 2013
Status
Patent Maintained As Amended
Nov 11, 2022
Grant Date
Dec 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

RICHLYJul 9, 2020RICHLY & RITSCHEL PATENTANWALTE PARTG MBBWITHDRAWN
STRAWMANJul 8, 2020POTTER CLARKSONWITHDRAWN

Patent Citations (48) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20070989574-
DESCRIPTIONUS20080026995-
DESCRIPTIONUS20080026998-
DESCRIPTIONUS20080056564-
DESCRIPTIONUS20080086231-
DESCRIPTIONUS20080097787-
DESCRIPTIONUS20080099844-
DESCRIPTIONUS2004171570
DESCRIPTIONUS2005130923
DESCRIPTIONUS2008039618
DESCRIPTIONUS2009012281
DESCRIPTIONUS2012214865
DESCRIPTIONUS6268490
DESCRIPTIONUS6525191
DESCRIPTIONUS6670461
DESCRIPTIONUS6770748
DESCRIPTIONUS6794499
DESCRIPTIONUS7034133
DESCRIPTIONUS7053207
DESCRIPTIONUS7399845
DESCRIPTIONUS7427672
DESCRIPTIONUS7547684
DESCRIPTIONUS7696345
DESCRIPTIONWO03004602
DESCRIPTIONWO2004106356
DESCRIPTIONWO2005021570
DESCRIPTIONWO2007134181
DESCRIPTIONWO2008101157
DESCRIPTIONWO2008150729
DESCRIPTIONWO2008154401
DESCRIPTIONWO2009006478
DESCRIPTIONWO2012012467
DESCRIPTIONWO2012092367
DESCRIPTIONWO2013030588
DESCRIPTIONWO9414226
DESCRIPTIONWO9839352
DESCRIPTIONWO9914226
EXAMINATIONWO2012012467
INTERNATIONAL-SEARCH-REPORTWO2012092367
OPPOSITIONUS2012214865
OPPOSITIONWO2010019270
OPPOSITIONWO2012012467
OPPOSITIONWO2012092367
OPPOSITIONWO2013082548
OPPOSITIONWO2013086207
SEARCHUS2012214865
SEARCHWO2012092367
SEARCHWO2013030588

Non-Patent Literature (NPL) Citations (82) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALBAEK et al., J. Org. Chem., (20060000), vol. 71, pages 7731 - 7740-
DESCRIPTION- ALTMANN et al., Biochem. Soc. Trans., (19960000), vol. 24, pages 630 - 637-
DESCRIPTION- ALTMANN et al., Chimia, (19960000), vol. 50, pages 168 - 176-
DESCRIPTION- ALTMANN et al., Nucleosides Nucleotides, (19970000), vol. 16, pages 917 - 926-
DESCRIPTION- ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, page 403 410-
DESCRIPTION- BAKER et al., J. Biol. Chem., (19970000), vol. 272, pages 11944 - 12000-
DESCRIPTION- BOXER et al., J. Neurol. Neurosurg. Psychiatry, (20110000), vol. 82, pages 196 - 203-
DESCRIPTION- BRAASCH et al., Chem. Biol., (20010000), vol. 8, pages 1 - 7-
DESCRIPTION- CHATTOPADHYAYA et al., J. Org. Chem., (20090000), vol. 74, pages 118 - 134-
DESCRIPTION- CHIO et al., Neurology, (20080000), vol. 70, pages 533 - 537-
DESCRIPTION- DEJESUS-HEMANDEZ et al., Neuron, (20110000), vol. 72, pages 245 - 256-
DESCRIPTION- DEJESUS-HERNANDEZ, Neuron, (20110000), vol. 72, no. 2, pages 245 - 256-
DESCRIPTION- DONNELLY et al., Annals of Neurology, (20120000), vol. 72, no. 16, pages S67 - S68-
DESCRIPTION- ELAYADI et al., Curr. Opinion Invest. Drugs, (20010000), vol. 2, pages 558 - 561-
DESCRIPTION- FREIER et al., Nucleic Acids Research, (19970000), vol. 25, no. 22, pages 4429 - 4443-
DESCRIPTION- FRIEDEN et al., Nucleic Acids Research, (20030000), vol. 21, pages 6365 - 6372-
DESCRIPTION- GAUTSCHI et al., J. Natl. Cancer Inst., (20010300), vol. 93, pages 463 - 471-
DESCRIPTION- "GENBANK", Database accession no. BQ068108.1-
DESCRIPTION- "GENBANK", Database accession no. BU194591.1-
DESCRIPTION- "GENBANK", Database accession no. DB079375.1-
DESCRIPTION- "GENBANK", Database accession no. DN993522.1-
DESCRIPTION- "GENBANK", Database accession no. NM _001256054.1-
DESCRIPTION- "GENBANK", Database accession no. NM 001256054.1-
DESCRIPTION- "GENBANK", Database accession no. NM_018325.3-
DESCRIPTION- "GENBANK", Database accession no. NM_145005.5-
DESCRIPTION- "GENBANK", Database accession no. NT -008413.18-
DESCRIPTION- "GENBANK", Database accession no. NT_008413.18-
DESCRIPTION- HIRTZ et al., Neurology, (20070000), vol. 68, pages 326 - 337-
DESCRIPTION- JOHNSON et al., Neuron, (20100000), vol. 68, pages 857 - 864-
DESCRIPTION- JONES, L.J. et al., Analytical Biochemistry, (19980000), vol. 265, pages 368 - 374-
DESCRIPTION- KOSHKIN et al., Tetrahedron, (19980000), vol. 54, pages 3607 - 3630-
DESCRIPTION- KUMAR et al., Bioorg. Med. Chem. Lett., (19980000), vol. 8, pages 2219 - 2222-
DESCRIPTION- KWIATKOWSKI et al., Science, (20090000), vol. 323, pages 1205 - 1208-
DESCRIPTION- LAAKSOVIRTA et al., Lancet Neurol., (20100000), vol. 9, pages 978 - 985-
DESCRIPTION- LEUMANN, Bioorg. Med. Chem., (20020000), vol. 10, pages 841 - 854-
DESCRIPTION- LILLO; HODGES, J. Clin. Neurosci., (20090000), vol. 16, pages 1131 - 1135-
DESCRIPTION- MAHER; DOLNICK, Nuc. Acid. Res., (19880000), vol. 16, pages 3341 - 3358-
DESCRIPTION- MARGOLIS et al., Hum. Mol. Genet., (20060000), vol. 15, pages 1808 - 1815-
DESCRIPTION- MARTIN, Helv. Chim. Acta, (19950000), vol. 78, pages 486 - 504-
DESCRIPTION- MARUYAMA et al., Nature, (20100000), vol. 465, pages 223 - 226-
DESCRIPTION- MORITA et al., Neurology, (20060000), vol. 66, pages 839 - 844-
DESCRIPTION- NEUMANN et al., Science, (20060000), vol. 314, pages 130 - 133-
DESCRIPTION- ORUM et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, pages 239 - 243-
DESCRIPTION- PEARSON et al., J. Nerol., (20110000), vol. 258, pages 647 - 655-
DESCRIPTION- RENTON et al., Neuron, (20110000), vol. 72, pages 257 - 268-
DESCRIPTION- RENTON, Neuron, (20110000), vol. 72, no. 2, pages 257 - 268-
DESCRIPTION- ROSEN et al., Nature, (19930000), vol. 362, pages 59 - 62-
DESCRIPTION- ROWLAND; SHNEIDER, N. Engl. J. Med., (20010000), vol. 344, pages 1688 - 1700-
DESCRIPTION- SHA et al., Alzheimers Res Ther., (20120000), vol. 4, no. 6, page 46-
DESCRIPTION- SINGH et al., Chem. Commun., (19980000), vol. 4, pages 455 - 456-
DESCRIPTION- SINGH et al., J. Org. Chem., (19980000), vol. 63, pages 10035 - 10039-
DESCRIPTION- SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482 489-
DESCRIPTION- SREEDHARAN et al., Science, (20080000), vol. 319, pages 1668 - 1672-
DESCRIPTION- SRIVASTAVA et al., J. Am. Chem. Soc., (20070000), vol. 129, no. 26, pages 8362 - 8379-
DESCRIPTION- VANCE et al., Brain, (20060000), vol. 129, pages 868 - 876-
DESCRIPTION- VANCE et al., Brain, (20090000), vol. 129, pages 868 - 876-
DESCRIPTION- WAHLESTEDT et al., Proc. Natl. Acad. Sci. U. S. A., (20000000), vol. 97, pages 5633 - 5638-
DESCRIPTION- WOOLF et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 7305 - 7309-
DESCRIPTION- ZHANG; MADDEN, Genome Res., (19970000), vol. 7, page 649 656-
EXAMINATION- SHARON J SHA ET AL, "Treatment implications of C9ORF72", ALZHEIMERS RES THER, London, UK, (20120216), vol. 4, no. 6, doi:10.1371/journal.pone.0029522, ISSN 1758-9193, page 46, XP055302455
INTERNATIONAL-SEARCH-REPORT- RENTON, AE A., "Hexanucleotide Repeat Expansion In C90RF72 Is The Cause Of Chromosome 9p21-Linked ALS-FTD.", NEURON, (20110914), vol. 72, no. 2, pages 257 - 268, XP028322561
INTERNATIONAL-SEARCH-REPORT- DEJESUS-HERNANDEZ, M., "Expanded GGGGCC Hexanucleotide Repeat In Noncoding Region Of C90RF72 Causes Chromosome 9p-Linked FTD And ALS.", NEURON., (20110914), vol. 72, no. 2, pages 245 - 256, XP028322560
OPPOSITION- A. Madsen, "Antisense Against C90RF72", MDA/ALS Newsmagazine, (20120701), pages 1 - 2, MDA/ALS Newsmagazine, URL: http://alsn.mda.org/article/antisense-against-c90rf72, (20160219), XP055251577-
OPPOSITION- Thurman M. Wheeler et al, "Targeting nuclear RNA for in vivo correction of myotonic dystrophy", Nature, (20120802), vol. 488, no. 7409, ISSN 00280836, pages 111 - 115-
OPPOSITION- WHEELER et al., Supplementary data, (20120000), pages 1 - 38-
OPPOSITION- DONNELLY CHRISTOPHER J ET AL, "Development of C9orf72 ALS Biomarkers and Therapeutics", Annals of Neurology, John Wiley and Sons, Boston , US, Boston , US, vol. 72, no. Suppl. 16, doi:10.1002/ana.23769, ISSN 0364-5134, pages S67 - S68, XP002757118
OPPOSITION- Jonathan K Watts, Et Al., "Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic", The Journal of Pathology, Longman, (20120101), vol. 226, no. 2, doi:10.1002/path.2993, ISSN 0022-3417, pages 365 - 379, XP055480533
OPPOSITION- Alan E. Renton et al, "A Hexanucleotide Repeat Expansion inIs the Cause of Chromosome 9p21-Linked ALS-FTD", Neuron, Cell Press, US, US, (20110914), vol. 72, no. 2, doi:10.1016/j.neuron.2011.09.010, ISSN 0896-6273, pages 257 - 268, XP028322561
OPPOSITION- Mariely DeJesus-Hernandez ET AL, "Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region ofCauses Chromosome 9p-Linked FTD and ALS", Neuron, Cell Press, US, US, (20110914), vol. 72, no. 2, doi:10.1016/j.neuron.2011.09.011, ISSN 0896-6273, pages 245 - 256, XP028322560
OPPOSITION- Jiang Jie et al, "Gain of Toxicity from ALS/FTD-Linked Repeat Expansions inC9ORF72Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs", Neuron, Cell Press, US, US, (20160421), vol. 90, no. 3, doi:10.1016/j.neuron.2016.04.006, ISSN 0896-6273, pages 535 - 550, XP029531466
OPPOSITION- Thurman M. Wheeler et al, "Targeting nuclear RNA for in vivo correction of myotonic dystrophy", Nature, (20120802), vol. 488, no. 7409, doi:10.1038/nature11362, ISSN 00280836, pages 111 - 115, XP055037666
OPPOSITION- Thurman M. Wheeler et al, "Targeting nuclear RNA for in vivo correction of myotonic dystrophy", Nature, �Macmillan Journals Ltd., etc.|, (20120802), vol. 488, no. 7409, doi:10.1038/nature11362, ISSN 00280836, pages 111 - 115, XP055037666
OPPOSITION- J. E. Lee, Bennett C. F., Cooper T. A., "RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1", Proceedings of the National Academy of Sciences, National Academy of Sciences, doi:10.1073/pnas.1117019109, ISSN 00278424, XP055035228
OPPOSITION- C. Lagier-Tourenne et al, "Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration", Proceedings of the National Academy of Sciences, National Academy of Sciences, US, US, (20131119), vol. 110, no. 47, doi:10.1073/pnas.1318835110, ISSN 0027-8424, pages E4530 - E4539, XP055228419
OPPOSITION- B. F. Boeve et al, "Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72", Brain, Oxford University Press, GB, GB, (20120301), vol. 135, no. 3, doi:10.1093/brain/aws004, ISSN 0006-8950, pages 765 - 783, XP055265380
OPPOSITION- P Dan Cook, "Medicinal Chemistry of Antisense Oligonucleotides", Antisense Drug Technology, Principles, Strategies and Applications, (20010101), pages 29 - 51, doi:10.1201/9781420002546.ch2, XP055427268
SEARCH- A. Madsen, "Antisense Against C90RF72", MDA/ALS Newsmagazine, (20120701), pages 1 - 2, URL: http://alsn.mda.org/article/antisense-against-c90rf72, (20160219), XP055251577 [I] 1-15 * the whole document * [Y] 1-15-
SEARCH- PETER K TODD ET AL, "RNA mediated neurodegeneration in repeat expansion disorders", ANNALS OF NEUROLOGY., BOSTON, US, (20091223), vol. 67, no. 3, doi:10.1002/ana.21948, ISSN 0364-5134, pages NA - NA, XP055269539 [A] 1-15 * the whole document *
SEARCH- DONNELLY CHRISTOPHER J ET AL, "Development of C9orf72 ALS Biomarkers and Therapeutics", ANNALS OF NEUROLOGY & 137TH ANNUAL MEETING OF THE AMERICAN-NEUROLOGICAL-ASSOCIATION (ANA); BOSTON, MA, USA; OCTOBER 07 -10, 2012, (20121007), vol. 72, no. Suppl. 16, pages S67 - S68, XP002757118 [I] 1-15 * the whole document * [Y] 1-15
SEARCH- ALANE RENTON ET AL, "A Hexanucleotide Repeat Expansion inIs the Cause of Chromosome 9p21-Linked ALS-FTD", NEURON, CELL PRESS, US, vol. 72, no. 2, doi:10.1016/J.NEURON.2011.09.010, ISSN 0896-6273, (20110914), pages 257 - 268, (20110917), XP028322561 [Y] 1-15 * the whole document *
SEARCH- MARIELY DEJESUS-HERNANDEZ ET AL, "Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region ofCauses Chromosome 9p-Linked FTD and ALS", NEURON, CELL PRESS, US, vol. 72, no. 2, doi:10.1016/J.NEURON.2011.09.011, ISSN 0896-6273, (20110914), pages 245 - 256, (20110917), XP028322560 [Y] 1-15 * the whole document *
SEARCH- S. A. M. MULDERS ET AL, "Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20090818), vol. 106, no. 33, doi:10.1073/pnas.0905780106, ISSN 0027-8424, pages 13915 - 13920, XP055007026 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents